Mycophenolate mofetil: An update

Maria Cristina Villarroel, Manuel Hidalgo, Antonio Jimeno

Research output: Contribution to journalArticle

Abstract

Mycophenolic acid (MPA) is a potent, selective, noncompetitive and reversible inhibitor of inosine-5′-monophosphate deshydrogenase (IMPDH). By depleting guanosine and deoxyguanosine nucleotides in T and B lymphocytes it inhibits their proliferation and, hence, immunoglobin (Ig) production. MPA also suppresses dendritic cell maturation decreasing its capacity of antigen presentation to T lymphocytes. MPA reduces the recruitment of monocytes into sites of graft rejection and inflammation. Mycophenolate mofetil (MMF) is a prodrug of MPA that was developed to improve the bioavailability of MPA. After oral administration, MMF is completely metabolized to MPA. A major inactive metabolite, mycophenolic acid glucuronide (MPAG), is formed after MPA glucuronidation. MPAG has an important role in the enterohepatic recirculation of MPA. MMF is approved for the prophylaxis of allograft rejection after renal, cardiac or liver transplant. The oral dose ranges from 1.0-1.5 g/day twice daily. Moreover, studies on the use of MMF in lung and simultaneous pancreas/kidney transplants have shown encouraging results. MMF also demonstrates potential in the treatment of autoimmune diseases such as lupus, myasthenia gravis and glomerular disorders. This review focuses on the molecular mechanism of action and pharmacological characteristics of MPA. Studies in both approved and non-approved applications are also summarized.

Original languageEnglish (US)
Pages (from-to)521-532
Number of pages12
JournalDrugs of Today
Volume45
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

Mycophenolic Acid
Molecular Mechanisms of Pharmacological Action
T-Lymphocytes
Transplants
Kidney
Inosine Monophosphate
Deoxyguanosine
Guanosine
Myasthenia Gravis
Antigen Presentation
Prodrugs
Graft Rejection

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Villarroel, M. C., Hidalgo, M., & Jimeno, A. (2009). Mycophenolate mofetil: An update. Drugs of Today, 45(7), 521-532. https://doi.org/10.1358/dot.2009.45.7.1384878

Mycophenolate mofetil : An update. / Villarroel, Maria Cristina; Hidalgo, Manuel; Jimeno, Antonio.

In: Drugs of Today, Vol. 45, No. 7, 07.2009, p. 521-532.

Research output: Contribution to journalArticle

Villarroel, MC, Hidalgo, M & Jimeno, A 2009, 'Mycophenolate mofetil: An update', Drugs of Today, vol. 45, no. 7, pp. 521-532. https://doi.org/10.1358/dot.2009.45.7.1384878
Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: An update. Drugs of Today. 2009 Jul;45(7):521-532. https://doi.org/10.1358/dot.2009.45.7.1384878
Villarroel, Maria Cristina ; Hidalgo, Manuel ; Jimeno, Antonio. / Mycophenolate mofetil : An update. In: Drugs of Today. 2009 ; Vol. 45, No. 7. pp. 521-532.
@article{5037fcc082844b21bcf6dbdd80be6e5e,
title = "Mycophenolate mofetil: An update",
abstract = "Mycophenolic acid (MPA) is a potent, selective, noncompetitive and reversible inhibitor of inosine-5′-monophosphate deshydrogenase (IMPDH). By depleting guanosine and deoxyguanosine nucleotides in T and B lymphocytes it inhibits their proliferation and, hence, immunoglobin (Ig) production. MPA also suppresses dendritic cell maturation decreasing its capacity of antigen presentation to T lymphocytes. MPA reduces the recruitment of monocytes into sites of graft rejection and inflammation. Mycophenolate mofetil (MMF) is a prodrug of MPA that was developed to improve the bioavailability of MPA. After oral administration, MMF is completely metabolized to MPA. A major inactive metabolite, mycophenolic acid glucuronide (MPAG), is formed after MPA glucuronidation. MPAG has an important role in the enterohepatic recirculation of MPA. MMF is approved for the prophylaxis of allograft rejection after renal, cardiac or liver transplant. The oral dose ranges from 1.0-1.5 g/day twice daily. Moreover, studies on the use of MMF in lung and simultaneous pancreas/kidney transplants have shown encouraging results. MMF also demonstrates potential in the treatment of autoimmune diseases such as lupus, myasthenia gravis and glomerular disorders. This review focuses on the molecular mechanism of action and pharmacological characteristics of MPA. Studies in both approved and non-approved applications are also summarized.",
author = "Villarroel, {Maria Cristina} and Manuel Hidalgo and Antonio Jimeno",
year = "2009",
month = "7",
doi = "10.1358/dot.2009.45.7.1384878",
language = "English (US)",
volume = "45",
pages = "521--532",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "7",

}

TY - JOUR

T1 - Mycophenolate mofetil

T2 - An update

AU - Villarroel, Maria Cristina

AU - Hidalgo, Manuel

AU - Jimeno, Antonio

PY - 2009/7

Y1 - 2009/7

N2 - Mycophenolic acid (MPA) is a potent, selective, noncompetitive and reversible inhibitor of inosine-5′-monophosphate deshydrogenase (IMPDH). By depleting guanosine and deoxyguanosine nucleotides in T and B lymphocytes it inhibits their proliferation and, hence, immunoglobin (Ig) production. MPA also suppresses dendritic cell maturation decreasing its capacity of antigen presentation to T lymphocytes. MPA reduces the recruitment of monocytes into sites of graft rejection and inflammation. Mycophenolate mofetil (MMF) is a prodrug of MPA that was developed to improve the bioavailability of MPA. After oral administration, MMF is completely metabolized to MPA. A major inactive metabolite, mycophenolic acid glucuronide (MPAG), is formed after MPA glucuronidation. MPAG has an important role in the enterohepatic recirculation of MPA. MMF is approved for the prophylaxis of allograft rejection after renal, cardiac or liver transplant. The oral dose ranges from 1.0-1.5 g/day twice daily. Moreover, studies on the use of MMF in lung and simultaneous pancreas/kidney transplants have shown encouraging results. MMF also demonstrates potential in the treatment of autoimmune diseases such as lupus, myasthenia gravis and glomerular disorders. This review focuses on the molecular mechanism of action and pharmacological characteristics of MPA. Studies in both approved and non-approved applications are also summarized.

AB - Mycophenolic acid (MPA) is a potent, selective, noncompetitive and reversible inhibitor of inosine-5′-monophosphate deshydrogenase (IMPDH). By depleting guanosine and deoxyguanosine nucleotides in T and B lymphocytes it inhibits their proliferation and, hence, immunoglobin (Ig) production. MPA also suppresses dendritic cell maturation decreasing its capacity of antigen presentation to T lymphocytes. MPA reduces the recruitment of monocytes into sites of graft rejection and inflammation. Mycophenolate mofetil (MMF) is a prodrug of MPA that was developed to improve the bioavailability of MPA. After oral administration, MMF is completely metabolized to MPA. A major inactive metabolite, mycophenolic acid glucuronide (MPAG), is formed after MPA glucuronidation. MPAG has an important role in the enterohepatic recirculation of MPA. MMF is approved for the prophylaxis of allograft rejection after renal, cardiac or liver transplant. The oral dose ranges from 1.0-1.5 g/day twice daily. Moreover, studies on the use of MMF in lung and simultaneous pancreas/kidney transplants have shown encouraging results. MMF also demonstrates potential in the treatment of autoimmune diseases such as lupus, myasthenia gravis and glomerular disorders. This review focuses on the molecular mechanism of action and pharmacological characteristics of MPA. Studies in both approved and non-approved applications are also summarized.

UR - http://www.scopus.com/inward/record.url?scp=71249141502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71249141502&partnerID=8YFLogxK

U2 - 10.1358/dot.2009.45.7.1384878

DO - 10.1358/dot.2009.45.7.1384878

M3 - Article

C2 - 19834629

AN - SCOPUS:71249141502

VL - 45

SP - 521

EP - 532

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 7

ER -